APA (7th ed.) Citation

M, F., S, R., C, S., E, T., A, G., M, R., . . . P, C. (2025). MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: Primary end point analysis from the CLL2-BZAG trial. Blood, 145(12), 1282. https://doi.org/10.1182/blood.2024026685

Chicago Style (17th ed.) Citation

M, Fürstenau, et al. "MRD-guided Zanubrutinib, Venetoclax, and Obinutuzumab in Relapsed CLL: Primary End Point Analysis from the CLL2-BZAG Trial." Blood 145, no. 12 (2025): 1282. https://doi.org/10.1182/blood.2024026685.

MLA (9th ed.) Citation

M, Fürstenau, et al. "MRD-guided Zanubrutinib, Venetoclax, and Obinutuzumab in Relapsed CLL: Primary End Point Analysis from the CLL2-BZAG Trial." Blood, vol. 145, no. 12, 2025, p. 1282, https://doi.org/10.1182/blood.2024026685.